Provider profile
Mabion.
Biologics CDMOs
Mabion describes cell line, process and analytical method development and clinical and commercial drug substance manufacturing of monoclonal antibodies and other therapeutic proteins using mammalian (CHO) and insect cell lines in single-use bioreactors. Drug product manufacturing is not documented on current pages. It lists its headquarters in Konstantynów Łódzki, Poland.
- Website
- mabion.eu (opens in a new tab)
- Sources reviewed
- November 3, 2026 · Source pages re-checked within 4 months
- First published
- November 3, 2026
This profile summarizes what public sources state about the provider, mostly its own website. It is not an audit, qualification or endorsement by ArgusBio. Confirm capabilities directly with the provider before contracting.
Services and capabilities
Services and capabilities
Development experience
Development experience
Development stage
Locations
Locations
- Konstantynów Łódzki, Poland · Headquarters6Described as the Medical Biotechnology Scientific and Industrial Complex; reviewed pages do not list separate manufacturing sites
Quality and regulatory
Quality and regulatory
The provider’s own materials state that it works to, or holds, the following. ArgusBio has not inspected or audited these claims.
- GMP / cGMP1
Unknowns and questions to ask
Unknowns and questions to ask
Public sources rarely establish what matters most for a specific project. Confirm directly:
- Available capacity, slot timing and scale for your next campaign
- Recent experience with your specific modality and expression system or chemistry
- Regulatory inspection history of the specific site that would manufacture your product
- Technology-transfer approach, timeline and who owns the resulting process knowledge
- Analytical and QC release testing done in-house versus subcontracted
- Quality agreement terms, batch-failure responsibility and change-order mechanics
Evidence and sources
Evidence and sources
- 1Biologics Process Development, Bioprocess, Drug Development (opens in a new tab)Mabion · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
- 2Cell Line Development - Mabion (opens in a new tab)Mabion · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
- 3Drug Substance Manufacturing of Biologics, Drug Product Development - Mabion (opens in a new tab)Mabion · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
- 4Analytical Method Development for Biologics - Mabion (opens in a new tab)Mabion · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
- 5Co-development - Mabion (opens in a new tab)Mabion · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
- 6Contact form - Mabion (opens in a new tab)Mabion · Provider website · retrieved November 3, 2026 · last checked November 3, 2026
“Last checked” means we confirmed the page was still available and still contained the cited statement. It does not mean ArgusBio verified the provider or its capabilities.
Something out of date or wrong? Request a correction. Corrections are reviewed against public sources before publication.
Contact
Contact
Contact the provider directly through its public contact page (opens in a new tab). ArgusBio does not forward inquiries to providers and does not receive referral fees.
ArgusBio sourcing
Need help evaluating this provider or comparing alternatives.
Discuss your sourcing need with ArgusBio. We can help define the scope, identify comparable alternatives and organize proposals so the decision stays yours.
Discuss a sourcing needWe work for the biotech, not the vendor. Vendors do not pay for inclusion or placement.